Glenmark Pharmaceuticals Limited has announced that a meeting of its Board of Directors will be held on Friday, January 30, 2026. The primary purpose of this meeting is to consider and approve the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2025.

In accordance with the company's "Code of Conduct for Prevention of Insider Trading" and SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for directors and designated persons will be closed from December 31, 2025, to February 01, 2026, inclusive. This closure is in effect for the purpose of approving the aforementioned financial results.